Platin-DRP®
Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About Chosa Oncology
Chosa Oncology is a private, pre-revenue diagnostics company focused on bringing tumor biology into platinum chemotherapy treatment decisions. Its core technology is the Platin-DRP®, a gene expression-based biomarker test designed to identify patients with solid tumors who are most likely to benefit from cisplatin or carboplatin. The company has presented multiple clinical validations in non-small cell lung cancer (NSCLC) and metastatic breast cancer and is positioning its test as a decision-support tool to improve precision in using these cornerstone therapies. Chosa is based in Stockholm, Sweden, and is led by a team with support from key opinion leaders in oncology.
View full company profileAbout Chosa Oncology
Chosa Oncology is a private, pre-revenue diagnostics company focused on bringing tumor biology into platinum chemotherapy treatment decisions. Its core technology is the Platin-DRP®, a gene expression-based biomarker test designed to identify patients with solid tumors who are most likely to benefit from cisplatin or carboplatin. The company has presented multiple clinical validations in non-small cell lung cancer (NSCLC) and metastatic breast cancer and is positioning its test as a decision-support tool to improve precision in using these cornerstone therapies. Chosa is based in Stockholm, Sweden, and is led by a team with support from key opinion leaders in oncology.
View full company profileAbout Chosa Oncology
Chosa Oncology is a private, pre-revenue diagnostics company focused on bringing tumor biology into platinum chemotherapy treatment decisions. Its core technology is the Platin-DRP®, a gene expression-based biomarker test designed to identify patients with solid tumors who are most likely to benefit from cisplatin or carboplatin. The company has presented multiple clinical validations in non-small cell lung cancer (NSCLC) and metastatic breast cancer and is positioning its test as a decision-support tool to improve precision in using these cornerstone therapies. Chosa is based in Stockholm, Sweden, and is led by a team with support from key opinion leaders in oncology.
View full company profileAbout Chosa Oncology
Chosa Oncology is a private, pre-revenue diagnostics company focused on bringing tumor biology into platinum chemotherapy treatment decisions. Its core technology is the Platin-DRP®, a gene expression-based biomarker test designed to identify patients with solid tumors who are most likely to benefit from cisplatin or carboplatin. The company has presented multiple clinical validations in non-small cell lung cancer (NSCLC) and metastatic breast cancer and is positioning its test as a decision-support tool to improve precision in using these cornerstone therapies. Chosa is based in Stockholm, Sweden, and is led by a team with support from key opinion leaders in oncology.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| Idylla EGFR Mutation Assay | Biocartis | Approved |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| Macrocyclic OMNI-EGFR Inhibitor | BlossomHill Therapeutics | Phase 1 |
| TUMORIN Clinical Trial | Nilogen Oncosystems | N/A (Diagnostic Validation) |
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| Lazertinib (Leclaza) | Genosco | Approved |
| IPH5201 (anti-CD39 mAb) | Orega Biotech | Phase 2 |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Aspyre Clinical Test for Lung | Biofidelity | Commercial |
| EGFR Mutation Detection Assay | Stilla Technologies | Assay Development/Validation |
| OX-4224 | OmRx Oncology | Phase 2 |